ClinicalTrials.gg
CompletedNCT04649229Updated Oct 27, 2026Results posted

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

A Phase 4 interventional study of LCZ 696 and Placebo in Heart Failure, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Yale University · Phase 4, Interventional, and Basic science

How we know

Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Heart Failure by Yale University — 9 open to participants now, 12 under way, none of them phase 3. Heart Failure · Yale University.

Enrollment
22nd of 27
46 · median 72
Started
2021
with 5 others
Phase 4
2 of 33
none open now
Registered
19th of 33
by date

Among the 33 studies in Heart Failure by Yale University, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2021, is one of 2 in phase 4, and was the 19th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 33 studies in Heart Failure by Yale University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Heart Failure by Yale University, or all of them as a file.
02

Study summary

This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).

Read the detailed description

LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality compared to enalapril in patients with heart failure (HF), reduced ejection fraction (EF), and increased brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) in the PARADIGM-HF trial. The PIONEER-HF study demonstrated the efficacy of LCZ696 in preventing rehospitalization in patients with acutely decompensated HF.

LCZ696 has been underutilized in heart failure, in part due to concerns about hypotension. NEP degrades several vasodilator peptides including bradykinin, substance P and brain-type natriuretic peptide. Decreased degradation of endogenous substance P could contribute to hypotension at initiation of LCZ696 through vasodilation or through increased natriuresis and diuresis. Antagonism of the NK1 receptor using aprepitant would be expected to prevent this effect.

Objectives

The main objectives of this mechanistic randomized, double-blind, crossover-design study are:

The primary objective is to test the hypothesis that endogenous substance P contributes to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis at initiation.

The secondary objective is to test the hypothesis that endogenous substance P contributes to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis after up-titration.

Eighty (80) subjects with stable heart failure who meet all inclusion/exclusion criteria will be enrolled. Subjects who qualify will collect their urine for 24 hours before each study day for measurement of volume, sodium and potassium. At the start of the study, they will stop their regular angiotensin-converting enzyme (ACE) inhibitor or ARB. After a 48-hour washout, they will undergo a study day in which they are given a single dose of 50 mg LCZ696. They will also receive either the NK1 receptor antagonist aprepitant or placebo vehicle in random order (double-blind). After a 96-hour washout, they will repeat the study day and receive a single dose of 50 mg LCZ696 and the opposite study drug (aprepitant or placebo). After completion of the two acute study days, subjects will take LCZ696 50 mg bid for two weeks, followed by LCZ696 100 mg bid for three weeks, and then LCZ696 200 mg bid, following the conservative up-titration protocol from the TITRATION study. Criteria for continuing up-titration appears in the full study protocol. On the 7th and 10th day of the 200 mg bid or highest tolerated dose, subjects will again undergo two more study days three days apart in which they are randomized to receive either aprepitant or placebo.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Black and white men and women
  2. Stable patients with a reduced (EF)

    1. EF ≤55%, and
    2. history of symptoms of (NYHA) class I, II, or III heart failure (HF)
    3. stable clinical symptoms including no hospitalizations for the last three months, or one month if hospitalized only once for initial diagnosis of HF
    4. who are not already taking LCZ696
  3. treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and with a beta blocker (unless or not tolerated) for at least four weeks
  4. for patients with NYHA Class II or III HF and EF ≤35%, treatment with a stable dose of an mineralocorticoid receptor (MR) antagonist for at least four weeks, unless not possible due to renal function or adverse reaction
  5. For female subjects, the following conditions must be met:

    1. status for at least one year
    2. status post-surgical sterilization
    3. or if , utilization of barrier methods of or an oral contraceptive and willingness to undergo urine β-HCG testing on every study day
  6. Age 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  1. History of or allergy to any of the study drugs, drugs of similar chemical classes, ACEi, ARBs, or neutral endopeptidase inhibitor (NEPi), as well as known or suspected to the study drugs
  2. History of angioedema
  3. History of decompensated HF within the last 3 months (exacerbation of chronic HF manifested by signs and symptoms that required intravenous therapy or hospitalization) or one month if hospitalized only once for initial diagnosis of HF
  4. History of heart transplant or on a transplant list or with left ventricular assistance device
  5. Symptomatic hypotension and/or a systolic blood pressure (SBP)\<100 mmHg at screening or \<95 mmHg during the study
  6. Serum potassium >5.2 mmol/L at screening or during the study
  7. Impaired renal function ( of \<30mL/min/1.73 m2) as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years:

    a. eGFR (mL/min/1.73 m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female)

  8. Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within six months prior to screening
  9. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening
  10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or with residual deficits
  11. History of ventricular arrhythmia with syncopal episodes
  12. Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker
  13. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular (LV) dilatation
  14. Presence of other hemodynamically significant obstructive lesions of the LV outflow tract, including aortic and subaortic stenosis
  15. Type 1 diabetes
  16. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c >9%
  17. In T2DM, dipeptidyl peptidase-4 inhibitor use for one month prior to enrollment will be excluded due to possible interaction with LCZ696
  18. Hematocrit \<35%
  19. Breast feeding and pregnancy
  20. History or presence of immunological or hematological disorders
  21. History of not felt to be cured, except non-melanoma skin cancer
  22. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week
  23. History of hypersensitivity reaction to contrast
  24. Clinically significant gastrointestinal impairment that could interfere with drug absorption
  25. History of pancreatitis or known pancreatic lesions
  26. Impaired hepatic function with evidence of advanced fibrosis or cirrhosis [stable (AST) and/or alanine amino transaminase (ALT) trend if >3.0 x as deemed of minimal clinical relevance by the investigators]
  27. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal anti-inflammatory drugs
  28. Treatment with greater than 5 mg of prednisone or equivalent dose of chronic systemic therapy within the last year or recent (within 6 weeks of first study day) treatment with burst dosed glucocorticoid therapy
  29. Treatment with lithium salts
  30. History of alcohol or drug abuse
  31. Treatment with any drug in the one month preceding the study
  32. Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
  33. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    placebo, aprepitant, placebo, aprepitant

    After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant 120 mg. All participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant 120 mg, respectively.

    Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant

  • Experimental
    placebo, aprepitant, aprepitant, placebo

    After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant 120 mg. Participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant 120 mg and placebo, respectively.

    Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant

  • Experimental
    aprepitant, placebo, placebo, aprepitant

    After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and aprepitant 120 mg. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant 120 mg, respectively.

    Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant

  • Experimental
    aprepitant, placebo, aprepitant, placebo

    After a 48-hr washout, participants in this arm will be given LCZ696 (sacubitril/valsartan) 50 mg and aprepitant 120 mg. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 (sacubitril/valsartan) over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant 120 mg and placebo, respectively.

    Drug: LCZ 696 · Drug: Placebo · Drug: Para-aminohippurate · Drug: Iohexol · Drug: Aprepitant

Interventions

  • DrugLCZ 696

    Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).

    Also known as: Entresto

  • DrugPlacebo

    Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4

  • DrugP-Aminohippuric AcidStudies of P-Aminohippuric AcidP-Aminohippuric Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.

  • DrugIohexol

    Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.

  • Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4

06

What researchers measure

Primary outcomes

  1. Max Change in Mean Arterial Pressure (MAP)

    Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days

    Time frame: The maximal change in MAP, as measured by the lowest MAP recorded six hours following drug administration minus the baseline MAP.

  2. Urine Sodium Excretion

    Urine sodium excretion will be measured for six hours following administration of LCZ696 on each of the four study days.

    Time frame: Total urine output from drug administration to six hours following drug administration

Secondary outcomes

  1. Heart Rate

    Heart rate (HR) will be measured before and after LCZ696 on each of the four study days

    Time frame: The maximum change in heart rate as measured by the highest heart rate recorded over six hours after drug administration minus the baseline heart rate.

  2. Urine Volume

    Urine volume will be measured for six hours following LCZ696 on each of the four study days.

    Time frame: Over six hours on each of four study days

  3. Renal Plasma Flow

    Renal plasma flow (RPF) will be calculated from para-aminohippurate clearance prior to and following LCZ696 and normalized per body surface area.

    Time frame: The change in renal plasma flow as measured by the renal plasma flow six hours following administration of the drug minus baseline renal plasma flow.

  4. Glomerular Filtration Rate

    Glomerular filtration rate (GFR) will be calculated from the clearance of iohexol prior to and following LCZ66 on each of the four study days and expressed as mL of blood cleared of creatinine per minute.

    Time frame: The glomerular rate or iohexol clearance calculated based on iohexol concentrations measured serially for six hours after drug administration.

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo, Aprepitant, Placebo, AprepitantPlacebo, Aprepitant, Aprepitant, PlaceboAprepitant, Placebo, Placebo, AprepitantAprepitant, Placebo, Aprepitant, Placebo
Started11121211
Finished study day 18111210
Finished study day 28111110
Completed uptitration of sacubitril/valsartan41096
Finished study day 341086
Completed41085
Not completed7246

Outcome measures

PrimaryMax Change in Mean Arterial Pressure (MAP)

Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days

Time frame:
The maximal change in MAP, as measured by the lowest MAP recorded six hours following drug administration minus the baseline MAP.
Reported as:
Mean · change in mmHg
Max Change in Mean Arterial Pressure (MAP)
change in mmHgPlaceboAprepitant
Max Change in Mean Arterial Pressure (MAP)-14.85 ± 10.23-12.37 ± 7.55
PrimaryUrine Sodium Excretion

Urine sodium excretion will be measured for six hours following administration of LCZ696 on each of the four study days.

Time frame:
Total urine output from drug administration to six hours following drug administration
Reported as:
Mean · mmol
Urine Sodium Excretion
mmolPlaceboAprepitant
Urine Sodium Excretion122.7 ± 56.3136.8 ± 74.1
SecondaryHeart Rate

Heart rate (HR) will be measured before and after LCZ696 on each of the four study days

Time frame:
The maximum change in heart rate as measured by the highest heart rate recorded over six hours after drug administration minus the baseline heart rate.
Reported as:
Mean · change in bpm
Heart Rate
change in bpmPlaceboAprepitant
Heart Rate12.81 ± 7.7215.30 ± 9.30
SecondaryUrine Volume

Urine volume will be measured for six hours following LCZ696 on each of the four study days.

Time frame:
Over six hours on each of four study days
Reported as:
Mean · mL
Urine Volume
mLPlaceboAprepitant
Urine Volume649.8 ± 337.0641.7 ± 300.0
SecondaryRenal Plasma Flow

Renal plasma flow (RPF) will be calculated from para-aminohippurate clearance prior to and following LCZ696 and normalized per body surface area.

Time frame:
The change in renal plasma flow as measured by the renal plasma flow six hours following administration of the drug minus baseline renal plasma flow.
Reported as:
Mean · change in mL/min/1.73m2
Renal Plasma Flow
change in mL/min/1.73m2PlaceboAprepitant
Renal Plasma Flow1.82 ± 111.916.7 ± 80.3
SecondaryGlomerular Filtration Rate

Glomerular filtration rate (GFR) will be calculated from the clearance of iohexol prior to and following LCZ66 on each of the four study days and expressed as mL of blood cleared of creatinine per minute.

Time frame:
The glomerular rate or iohexol clearance calculated based on iohexol concentrations measured serially for six hours after drug administration.
Reported as:
Median · mL/min
Glomerular Filtration Rate
mL/minPlaceboAprepitant
Glomerular Filtration Rate83.1 ± 36.870.6 ± 29.5

Adverse events

Collected over Seven to eight weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior to First Study Day0/46 (0%)1/46 (2.2%)0/46 (0%)
Acute Study Day Placebo0/40 (0%)0/40 (0%)2/40 (5%)
Acute Study Day Aprepitant0/41 (0%)0/41 (0%)1/41 (2.4%)
LCZ699 (Entresto) Uptitration Period 50 mg Bid0/37 (0%)1/37 (2.7%)2/37 (5.4%)
LCZ699 (Entresto) Uptitration Period 100 mg Bid0/32 (0%)1/32 (3.1%)1/32 (3.1%)
LCZ699 (Entresto) Uptitration Period 200 mg Bid0/29 (0%)0/29 (0%)1/29 (3.4%)
Chronic Study Plus Placebo0/28 (0%)0/28 (0%)1/28 (3.6%)
Chronic Study Day Plus Aprepitant0/27 (0%)0/27 (0%)1/27 (3.7%)
Most frequent serious events
Most frequent serious events
EventPrior to First Study DayAcute Study Day PlaceboAcute Study Day AprepitantLCZ699 (Entresto) Uptitration Period 50 mg BidLCZ699 (Entresto) Uptitration Period 100 mg BidLCZ699 (Entresto) Uptitration Period 200 mg BidChronic Study Plus PlaceboChronic Study Day Plus Aprepitant
fluid overlaodCardiac disorders0/460/400/410/371/320/290/280/27
SyncopeCardiac disorders0/460/400/411/370/320/290/280/27
abscessInfections and infestations1/460/400/410/370/320/290/280/27
Most frequent other events
Most frequent other events
EventPrior to First Study DayAcute Study Day PlaceboAcute Study Day AprepitantLCZ699 (Entresto) Uptitration Period 50 mg BidLCZ699 (Entresto) Uptitration Period 100 mg BidLCZ699 (Entresto) Uptitration Period 200 mg BidChronic Study Plus PlaceboChronic Study Day Plus Aprepitant
hypotensionVascular disorders0/460/401/412/370/320/291/281/27
intravenous catheter infiltrationInvestigations0/462/400/410/370/320/290/281/27
atrial fibrillationCardiac disorders0/460/400/410/371/321/290/280/27

Baseline characteristics

participants who completed four study days

Age, Continuous
Age, Continuous(years)Placebo, Aprepitant, Placebo, AprepitantPlacebo, Aprepitant, Aprepitant, PlaceboAprepitant, Placebo, Placebo, AprepitantAprepitant, Placebo, Aprepitant, PlaceboTotal
Mean61.97 ± 3.2251.32 ± 14.5556.72 ± 13.8759.12 ± 18.3457.25 ± 14.09
Sex: Female, Male
Sex: Female, Male(Participants)Placebo, Aprepitant, Placebo, AprepitantPlacebo, Aprepitant, Aprepitant, PlaceboAprepitant, Placebo, Placebo, AprepitantAprepitant, Placebo, Aprepitant, PlaceboTotal
Female21328
Male295420
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo, Aprepitant, Placebo, AprepitantPlacebo, Aprepitant, Aprepitant, PlaceboAprepitant, Placebo, Placebo, AprepitantAprepitant, Placebo, Aprepitant, PlaceboTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American233311
White255315
More than one race01001
Unknown or Not Reported00000
Ejection fraction
Ejection fraction(percent)Placebo, Aprepitant, Placebo, AprepitantPlacebo, Aprepitant, Aprepitant, PlaceboAprepitant, Placebo, Placebo, AprepitantAprepitant, Placebo, Aprepitant, PlaceboTotal
Median35.00 ± 12.2437.50 ± 10.7738.75 ± 12.2738.00 ± 10.7037.50 ± 10.54
08

Study locations

1 site
  • Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
09

References and documents

Publications

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. PubMed 25176015 ↗
  • Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. PubMed 30415601 ↗
  • Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gomez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548. Epub 2016 May 12. PubMed 27170530 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in May 2025, 47 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's 47 months is above that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Dec 2, 2020
StartActual
May 27, 2021
Primary completionActual
May 22, 2025
CompletionActual
May 22, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedMax Change in Mean arterial pressureArterial Pressure (MAP)Time frame: Over six hours on each of the four study days → The maximal change in MAP, as measured by the lowest MAP recorded six hours following drug administration minus the baseline MAP.
  • EditedUrine sodium excretionSodium ExcretionTime frame: Total urine output from drug administration to six hours following drug administration
Oct 27, 2026
Secondary outcomes
4 edited, 1 removed
What changed in the outcomes
  • EditedHeart rateRateTime frame: Over six hours on each of four study days → The maximum change in heart rate as measured by the highest heart rate recorded over six hours after drug administration minus the baseline heart rate.
  • EditedUrine volumeVolumeTime frame: Over six hours on each of four study days
  • EditedRenal plasma flowPlasma FlowTime frame: Over six hours on each of four study days → The change in renal plasma flow as measured by the renal plasma flow six hours following administration of the drug minus baseline renal plasma flow.
  • EditedGlomerular filtration rateFiltration RateTime frame: Over six hours on each of four study days → The glomerular rate or iohexol clearance calculated based on iohexol concentrations measured serially for six hours after drug administration.
  • RemovedUrine albumin-to-creatinine ratioTime frame: Over six hours on each of four study days
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedMax Change in Mean arterial pressureArterial Pressure (MAP)Time frame: Over six hours on each of the four study days → The maximal change in MAP, as measured by the lowest MAP recorded six hours following drug administration minus the baseline MAP.
    • EditedUrine sodium excretionSodium ExcretionTime frame: Total urine output from drug administration to six hours following drug administration
    Secondary outcomes 4 edited, 1 removed
    What changed in the outcomes
    • EditedHeart rateRateTime frame: Over six hours on each of four study days → The maximum change in heart rate as measured by the highest heart rate recorded over six hours after drug administration minus the baseline heart rate.
    • EditedUrine volumeVolumeTime frame: Over six hours on each of four study days
    • EditedRenal plasma flowPlasma FlowTime frame: Over six hours on each of four study days → The change in renal plasma flow as measured by the renal plasma flow six hours following administration of the drug minus baseline renal plasma flow.
    • EditedGlomerular filtration rateFiltration RateTime frame: Over six hours on each of four study days → The glomerular rate or iohexol clearance calculated based on iohexol concentrations measured serially for six hours after drug administration.
    • RemovedUrine albumin-to-creatinine ratioTime frame: Over six hours on each of four study days
    + 3 other changes: verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04649229
Lead sponsor
Yale University
Responsible party
Nancy Brown (Professor of Internal Medicine, Yale University) — Principal investigator
First posted
Dec 2, 2020
Start date
May 27, 2021
Primary completion
May 22, 2025
Completion
May 22, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Nancy J. Brown, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion